Thermo Fisher Scientific Inc. (TSX:TMO)
Canada · Delayed Price · Currency is CAD | Market Cap | 229.88B +3.6% |
| Revenue (ttm) | 62.70B +5.4% |
| Net Income | 9.50B +5.1% |
| EPS | 25.24 +6.7% |
| Shares Out | n/a |
| PE Ratio | 24.20 |
| Forward PE | 17.72 |
| Dividend | 0.06 (0.39%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | n/a |
| Average Volume | 36,166 |
| Open | 16.63 |
| Previous Close | 16.68 |
| Day's Range | 16.35 - 16.63 |
| 52-Week Range | 14.22 - 23.30 |
| Beta | n/a |
| RSI | 35.89 |
| Earnings Date | Apr 23, 2026 |
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and... [Read more]
Financial Performance
In 2025, Thermo Fisher Scientific's revenue was $44.56 billion, an increase of 3.91% compared to the previous year's $42.88 billion. Earnings were $6.70 billion, an increase of 5.82%.
Financial numbers in USD Financial StatementsNews
Nalgene Outdoor Introduces Fresh Flow™ Straw Bottle
ROCHESTER, N.Y.--(BUSINESS WIRE)--Nalgene Outdoor today introduces the Fresh Flow™ straw bottle, a new addition to its reusable bottle collection designed to give fans more ways to hydrate without sac...
Thermo Fisher Scientific's Clinical Research Business Named a Leader Among CROs in 2026 ISG Provider Lens™ Report for Use of AI in Clinical Trials
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, earned a Leader designation among contract research organizations (CROs) in the 2026 ISG Provider L...
Thermo Fisher Scientific Unveils an Integrated Platform to Advance Scalable Cell Therapy Manufacturing
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Gibco™ CTS™ DynaXS™ Single Use Bioreactor, a purpose-built expansion platform ...
Thermo Fisher Scientific Opens U.S. Flagship Bioprocess Design Center to Accelerate the Delivery of Life-changing Therapies
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the opening of its flagship U.S. Bioprocess Design Center (BDC) at the company's Pl...
Thermo Fisher Scientific to Host Investor Day
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, will hold its 2026 Investor Day on Wednesday, May 20, 2026, starting at 9:00 a.m. ET in...
Thermo Fisher to Sell Microbiology Business to Astorg
Thermo Fisher Scientific has struck a deal to sell its microbiology business to European private-equity firm Astorg for about $1.075 billion.
Thermo Fisher price target lowered to $620 from $670 at Morgan Stanley
Morgan Stanley analyst Kallum Titchmarsh lowered the firm’s price target on Thermo Fisher (TMO) to $620 from $670 and keeps an Overweight rating on the shares. Investors “were clearly looking…
Thermo Fisher to sell microbiology business to Astorg for $1.075B
Thermo Fisher (TMO) Scientific has signed a definitive agreement to sell its microbiology business to Astorg for consideration of approximately $1.075B, consisting of cash and a $50M seller note. The…
Thermo Fisher to sell its microbiology business to Astorg for about $1.08 billion
Thermo Fisher Scientific said on Monday it has agreed to sell its microbiology business to a pan-European private equity firm Astorg for about $1.08 billion, consisting of cash and a $50...
Thermo Fisher Scientific Signs Agreement to Sell its Microbiology Business to Astorg
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has signed a definitive agreement to sell its microbiology busi...
Thermo Fisher price target lowered to $600 from $700 at Stifel
Stifel analyst Daniel Arias lowered the firm’s price target on Thermo Fisher (TMO) to $600 from $700 and keeps a Buy rating on the shares.
Thermo Fisher price target lowered to $639 from $653 at Baird
Baird analyst Catherine Ramsey Schulte lowered the firm’s price target on Thermo Fisher (TMO) to $639 from $653 and keeps an Outperform rating on the shares. The firm updated its…
Thermo Fisher sees Q2 EPS $5.69-$5.74, consensus $5.81
Sees Q2 organic revenue growth 3%. Guidance taken from Q1 earnings conference call.
Thermo Fisher raises FY26 adjusted EPS view to $24.64-$25.12 from $24.22-$24.80
Consensus $24.80. Raises FY26 revenue view to $47.3B-$48.1B from $46.3B-$47.2B, consensus $47.7B. Says guidance raise reflects strong start to year and Clario acquisition. Says guidance assumes 3%-4% ...
Thermo Fisher Scientific Earnings Call Transcript: Q1 2026
Q1 saw 6% revenue and adjusted EPS growth, driven by pharma/biotech strength and the Clario acquisition. Full-year guidance was raised for both revenue and EPS, with strong segment performance and ongoing innovation offsetting inflation and macro headwinds.
Thermo Fisher posts quarterly results beat as lab products, biopharma services grow
Thermo Fisher Scientific on Thursday reported first-quarter profit and revenue above Wall Street estimates, as growth in its laboratory products and biopharma services business helped offset softnes...
Thermo Fisher reports Q1 adjusted EPS $5.44, consensus $5.24
Reports Q1 revenue $11.01B, consensus $10.86B. “We delivered a strong start to the year, reflecting excellent execution by our team, as we leveraged the PPI Business System to drive operational…
Thermo Fisher Scientific Reports First Quarter 2026 Results
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 28, 2026. First ...
Thermo Fisher Scientific Launches Applied Biosystems™ PowerFlex™ Thermal Cycler to Advance PCR Flexibility and Productivity
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the Applied Biosystems™ PowerFlex™ Thermal Cycler, a next-generation polymerase cha...
Thermo Fisher price target lowered to $625 from $650 at Barclays
Barclays lowered the firm’s price target on Thermo Fisher (TMO) to $625 from $650 and keeps an Overweight rating on the shares. The firm adjusted targets in the life science…
Thermo Fisher Scientific's PPD Clinical Research Business Collaborates with HealthVerity to Expand Real-World Data Capabilities
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced a strategic data collaboration with HealthVerity, a leading real-world data (RWD) market...
Thermo Fisher announces collaboration with Precision Health Research
Thermo Fisher (TMO) Scientific announced a strategic collaboration with Precision Health Research, Singapore to advance the PRECISE-SG100K study, one of the region’s most ambitious and diverse populat...
Thermo Fisher Scientific Expands Global Biobank Leadership Through Strategic Collaboration with PRECISE-SG100K Singapore to Advance Population-Scale Proteomics
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced a strategic collaboration with Precision Health Research, Singapore (PR...
Citi adds ‘upside 90-day catalyst watch’ on Thermo Fisher
Citi analyst Patrick Donnelly added an “upside 90-day catalyst watch” on shares of Thermo Fisher (TMO) while keeping a Buy rating on the name with a $685 price target ahead…